Erythroid differentiation of human induced pluripotent stem cells is independent of donor cell type of origin
Isabel Dorn,
Katharina Klich,
Marcos J. Arauzo-Bravo,
Martina Radstaak,
Simeon Santourlidis,
Foued Ghanjati,
Teja F. Radke,
Olympia E. Psathaki,
Gunnar Hargus,
Jan Kramer,
Martin Einhaus,
Jeong Beom Kim,
Gesine Kögler,
Peter Wernet,
Hans R. Schöler,
Peter Schlenke,
Holm Zaehres
Affiliations
Isabel Dorn
Max Planck Institute for Molecular Biomedicine, Münster, Germany;Pediatric Hematology and Oncology, University Hospital Münster, Germany
Katharina Klich
Max Planck Institute for Molecular Biomedicine, Münster, Germany;Institute for Transfusion Medicine and Transplantation Immunology, University Hospital Münster, Germany
Marcos J. Arauzo-Bravo
Group of Computational Biology and Systems Biomedicine, Biodonostia Health Research Institute, San Sebastián, Spain;IKERBASQUE, Basque Foundation for Science, Bilbao, Spain
Martina Radstaak
Max Planck Institute for Molecular Biomedicine, Münster, Germany
Simeon Santourlidis
Institute for Transplantation Diagnostics and Cell Therapeutics, Heinrich-Heine-University Düsseldorf, Germany
Foued Ghanjati
Institute for Transplantation Diagnostics and Cell Therapeutics, Heinrich-Heine-University Düsseldorf, Germany
Teja F. Radke
Institute for Transplantation Diagnostics and Cell Therapeutics, Heinrich-Heine-University Düsseldorf, Germany
Olympia E. Psathaki
Max Planck Institute for Molecular Biomedicine, Münster, Germany
Gunnar Hargus
Max Planck Institute for Molecular Biomedicine, Münster, Germany;Institute for Neuropathology, University Hospital Münster, Germany
Jan Kramer
Medical Department I, University of Lübeck, Germany;LADR GmbH, Geesthacht, Germany
Martin Einhaus
LADR GmbH, Geesthacht, Germany
Jeong Beom Kim
UNIST, Ulsan National Institute of Science and Technology, Ulsan, Republic of Korea
Gesine Kögler
Institute for Transplantation Diagnostics and Cell Therapeutics, Heinrich-Heine-University Düsseldorf, Germany
Peter Wernet
Institute for Transplantation Diagnostics and Cell Therapeutics, Heinrich-Heine-University Düsseldorf, Germany
Hans R. Schöler
Max Planck Institute for Molecular Biomedicine, Münster, Germany;Faculty of Medicine, University of Münster, Germany
Peter Schlenke
Institute for Transfusion Medicine and Transplantation Immunology, University Hospital Münster, Germany;Clinics for Blood Group Serology and Transfusion Medicine, Medical University Graz, Austria
Holm Zaehres
Max Planck Institute for Molecular Biomedicine, Münster, Germany
Epigenetic memory in induced pluripotent stem cells, which is related to the somatic cell type of origin of the stem cells, might lead to variations in the differentiation capacities of the pluripotent stem cells. In this context, induced pluripotent stem cells from human CD34+ hematopoietic stem cells might be more suitable for hematopoietic differentiation than the commonly used fibroblast-derived induced pluripotent stem cells. To investigate the influence of an epigenetic memory on the ex vivo expansion of induced pluripotent stem cells into erythroid cells, we compared induced pluripotent stem cells from human neural stem cells and human cord blood-derived CD34+ hematopoietic stem cells and evaluated their potential for differentiation into hematopoietic progenitor and mature red blood cells. Although genome-wide DNA methylation profiling at all promoter regions demonstrates that the epigenetic memory of induced pluripotent stem cells is influenced by the somatic cell type of origin of the stem cells, we found a similar hematopoietic induction potential and erythroid differentiation pattern of induced pluripotent stem cells of different somatic cell origin. All human induced pluripotent stem cell lines showed terminal maturation into normoblasts and enucleated reticulocytes, producing predominantly fetal hemoglobin. Differences were only observed in the growth rate of erythroid cells, which was slightly higher in the induced pluripotent stem cells derived from CD34+ hematopoietic stem cells. More detailed methylation analysis of the hematopoietic and erythroid promoters identified similar CpG methylation levels in the induced pluripotent stem cell lines derived from CD34+ cells and those derived from neural stem cells, which confirms their comparable erythroid differentiation potential.